

2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE
PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING
THE SAME

The present invention relates in particular to 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, to the preparation thereof, to compositions containing them, and to the use thereof as a medicament.


More particularly, and according to a first aspect, the invention relates to 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines that can be used as anticancer agents.

2-Methoxy-3,4,5-trihydroxyalkylamides have been described in US 6239127, US 20010044433 A1, WO 01/85697, WO 00/29382, US 4831135, EP 687673 and US 2002128474 A1. These documents essentially disclose bengamide analogues and derivatives, bengamide being a natural product isolated from a marine sponge, *Jaspis coriacea*.

These same products have been described in the literature: J. Org. Chem. (1986), 51(23), 4494-7; J. Org. Chem. (2001), 66(5), 1733-41; J. Med. Chem. 2001, 44, 3692-9.

The problem that the present invention is intended to solve is that of obtaining new products with anticancer activity. In addition to maintaining an anticancer activity, some of these new products may also have advantageous properties in relation to their pharmacological activity, such as their pharmacokinetics, bioavailability, solubility, stability, toxicity, absorption or metabolism.


A subject of the present invention is the products corresponding to the following formula (I):



in which:

- a) R_1 is independently selected from the group consisting of (C_1-C_{12}) alkyl, (C_2-C_{12}) alkenyl, (C_2-C_{12}) alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkyl (C_1-C_{12}) alkyl, cycloalkyl (C_2-C_{12}) alkenyl, cycloalkyl (C_2-C_{12}) alkynyl, heterocyclyl (C_1-C_{12}) alkyl, heterocyclyl (C_2-C_{12}) alkenyl, heterocyclyl (C_2-C_{12}) alkynyl, aryl (C_1-C_{12}) alkyl, aryl (C_2-C_{12}) alkenyl, aryl (C_2-C_{12}) alkynyl, heteroaryl (C_1-C_{12}) alkyl, heteroaryl (C_2-C_{12}) alkenyl, heteroaryl (C_2-C_{12}) alkynyl, the aryl group of each R_1 being optionally substituted with one or more halogens;
- b) R_2 is selected from the group consisting of (C_1-C_6) alkyl, aryl (C_1-C_6) alkyl, heteroaryl (C_1-C_6) alkyl, aryl, heteroaryl, (C_1-C_6) alkylthio (C_1-C_6) alkyl, di (C_1-C_6) alkylamino (C_1-C_6) alkyl, aryloxy (C_1-C_6) alkyl, (C_1-C_6) alkoxy (C_1-C_6) alkyl;
- c) R_3 is selected from the group consisting of H, $COO(R_5)$, $CONH(R_5)$, $CO(R_5)$, $O(R_5)$ and R_5 ;
- d) R_4 is independently selected from the group consisting of F, Cl, Br, $N(R_5)_2$, NO_2 , CN, $COO(R_5)$, $CON(R_5)_2$, $NHCO(R_5)$, $NHCOO(R_5)$, $OCONH(R_5)$, $O(R_5)$ and R_5 , or else two substituents R_4 , attached to 2 adjacent carbons of the phenyl, together form a ring selected from a cycloalkyl, heterocyclyl, aryl or heteroaryl, optionally substituted with one or more R_4 ;
- e) m has the value 0, 1, 2, 3 or 4;
- f) R_5 is independently selected from a doublet of nonbonding electrons, H, (C_1-C_{12}) alkyl, (C_2-C_{12}) alkenyl, (C_2-C_{12}) alkynyl, halo (C_1-C_{12}) alkyl, aryl (C_1-C_{12}) alkyl, heteroaryl (C_1-C_{12}) alkyl, heteroarylaryl (C_1-C_{12}) alkyl, aryl,

heteroaryl and cycloalkyl, in which each R_5 is optionally substituted with at least one substituent selected from OH, halogen, (C_1-C_4) alkyl, (C_1-C_4) alkoxy, aryl (C_1-C_4) alkyl, aryl, heteroaryl (C_1-C_4) alkyl, heteroaryl, $-N(CH_3)_2$, $-NH_2$, $CONH_2$,



5

each of the R_z is independently selected from the group consisting of H, $COO(R_5)$, $CONH(R_5)$, $CON(R_5)_2$, $CO(R_5)$ and R_5 , in which each R_5 is independently selected from (C_1-C_4) alkyl, halo (C_1-C_4) alkyl, aryl (C_1-C_4) alkyl and heteroaryl (C_1-C_4) alkyl, in which each R_5 is optionally substituted with a substituent selected from OH, halogen, (C_1-C_4) alkyl, (C_1-C_4) alkoxy, aryl (C_1-C_4) alkyl, aryl, heteroaryl (C_1-C_4) alkyl and heteroaryl;

10

with the proviso that, when R_1 is $(E) -CH=CH-C(CH_3)_3$, R_2 is methyl and R_3 is H, then m is other than 0.

A subject of the present invention is the products of formula (I) below in which R_1 is independently selected from the group consisting of (C_1-C_{12}) alkyl, (C_2-C_{12}) alkenyl, (C_2-C_{12}) alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aryl (C_1-C_{12}) alkyl, aryl (C_2-C_{12}) alkenyl, aryl (C_2-C_{12}) alkynyl, heteroaryl (C_1-C_{12}) alkyl, heteroaryl (C_2-C_{12}) alkenyl and heteroaryl (C_2-C_{12}) alkynyl.

15

A subject of the present invention is the products of formula (I) below in which R_2 is selected from the group consisting of (C_1-C_6) alkyl, aryl (C_1-C_6) alkyl, heteroaryl (C_1-C_6) alkyl, aryl, heteroaryl, (C_2-C_{12}) alkenylaryl, (C_2-C_{12}) alkenylheteroaryl, (C_1-C_6) alkylthio (C_1-C_6) alkyl, di (C_1-C_6) alkylamino (C_1-C_6) alkyl and aryloxy (C_1-C_6) alkyl.

20

According to the invention, R_1 is preferably selected from $-C(R_6)=C(R_7)(R_8)$ in which R_6 , R_7 , are R_8 are independently selected from H, (C_1-C_6) alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl.

25

More preferably, R_1 is selected from $(E) -CH=CH-CH(CH_3)(C_2H_5)$,

(E) $\text{CH}=\text{CH}-\text{CH}(\text{CH}_3)_2$ and (E) $-\text{CH}=\text{CH}-\text{C}(\text{CH}_3)_3$, or else from (E) $-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}(\text{CH}_3)(\text{C}_2\text{H}_5)$, (E) $-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}(\text{CH}_3)_2$ and (E) $-\text{C}(\text{CH}_3)=\text{CH}-\text{C}(\text{CH}_3)_3$.

More preferably, R_1 is selected from (E) $-\text{CH}=\text{CH}-\text{C}_5\text{H}_9$.

- 5 According to the invention, R_2 is preferably methyl.


Among the subjects of the present invention, a first group is characterized in that R_3 is independently selected from: a methyl group or a (3,5-difluorophenyl)methyl group. A second group is characterized in that R_3 is H.

- 10 Among the subjects of the present invention, a third group is characterized in that R_4 is independently selected from: F, Cl, Br, phenyl and pyridinyl. A fourth group is characterized in that m is 0.

Preferably, the invention relates to the products exemplified in Table 1.

- 15 According to another aspect, the invention relates to the processes for preparing the products of formula (I) or (I'). The products of formula (I') are optionally active precursors of the products of formula (I). The products of formula (I) are obtained from the products of formula (I') by means of processes that have been described or by means of one or more reactions that are conventional for those skilled in the art, for instance a
20 cyclopropanation, an oxidation or a chiral separation.

The products of formula (I) or (I') can be obtained by hydrolysis of a product of formula (II):




(II)


, in which R_1 , R_2 , R_3 , R_4 and m are

as defined above.

The products of formula (II) can be obtained by reaction of a product of formula (III):




, in which R_3 , R_4 and m are as defined above, with a product of formula (IV):




5 , in which R_1 and R_2 are as defined above.

The products of formula (I) or (I') can also be obtained by reaction of a product of formula (III) as defined above, with a product of formula (V):




, in which R_1 and R_2 are as defined above.

10 The products of formula (V) can be obtained by hydrolysis of a product of formula (IV):




, in which R_1 and R_2 are as defined above. Products of formula (V) for which R_1 is $-\text{CH}=\text{CH}-\text{R}'_1$ can also be obtained by hydrolysis of a product of formula (VII):




, in which R_2 is as defined above, in order to obtain a

product of formula (VI):




, in which R_2 is as defined above, which is subjected to a metathesis in order to obtain a product of formula (V):



5 for which R_1 is $-\text{CH}=\text{CH}-\text{R}'_1$ and R'_1 is a (C_1-C_6) alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group.

The products of formula (VII) can be obtained by double dehydration of a product of formula (VIII):



, in which R_2 is as defined above.

10 The products of formulae (I') and (II) as defined above, with the exception of those for which R_1 is (E) $-\text{CH}=\text{CH}-\text{C}(\text{CH}_3)_3$, R_2 is methyl, R_3 is H and m is 0, are a subject of the present invention.

15 The products of formula (III) for which R_3 is H, methyl or (3,5-difluorophenyl)-methyl and R_4 is a bromine atom or a phenyl or else m has the value 0, with the exception of those for which R_3 is H and m has the value 0, are a subject of the present invention.

The products of formulae (IV) and (V) for which R_2 is methyl and R_1 is (E) $-\text{CH}=\text{CH}-\text{C}_5\text{H}_9$, are a subject of the present invention.

20 The products of formula (VI) for which R_2 is methyl, are a subject of the present invention. The products of formula (VII) for which R_2 is methyl, are a subject of the present invention.

The products according to the present invention can exist in the form of bases, of addition salts with acids, of solvates, of hydrates or of prodrugs.

The products according to the invention can be in nonchiral form or racemic form, or in a form enriched in a stereoisomer or in a form enriched in an enantiomer; and can optionally be salified. The products for which the carbon
5 attached to the exocyclic amine is in the (S) configuration are preferred.

A product in accordance with the invention may be used for the manufacture of a medicament that can be used for preventing or treating a pathological condition, in particular a cancer.

10 The products of the present invention can also be used for the manufacture of a medicament that can be used for preventing or treating a pathological condition in which neovascularization or angiogenesis takes place in an inappropriate manner, i.e. in cancers in general, and in specific cancers such as Kaposi's sarcoma or infantile haemangioma, but also in rheumatoid
15 arthritis, osteoarthritis and/or related pain, inflammatory bowel diseases such as ulcerative colitis or Crohn's disease, eye pathologies such as age-related macular degeneration or diabetic retinopathies, chronic inflammation and psoriasis.

Angiogenesis is a process for generating new blood capillaries from pre-existing vessels. Tumour angiogenesis (formation of new blood vessels),
20 which is essential to tumour growth, is also one of the essential factors of metastatic dissemination (Oncogene. 2003 May 19; 22(20):3172-9; Nat Med. 1995 Jan ;1(1):27-31).

The present invention also relates to the therapeutic compositions containing
25 a compound according to the invention, in combination with an excipient that is pharmaceutically acceptable according to the chosen method of administration. The pharmaceutical composition may be in solid or liquid form or in the form of liposomes.

Among the solid compositions, mention may be made of powders, gelatin

capsules and tablets. Among the oral forms, solid forms protected against the acidic medium of the stomach may also be included. The supports used for the solid forms consist in particular of mineral supports such as phosphates or carbonates, or organic supports such as lactose, celluloses, starch or polymers. The liquid forms consist of solutions, suspensions or dispersions. They contain, as dispersive support, either water or an organic solvent (ethanol, NMP or the like) or mixtures of surfactants and solvents or of complexing agents and solvents.

The liquid forms will preferably be injectable and, as a result, will have a formulation that is acceptable for such a use.

Acceptable routes of administration by injection include intravenous, intraperitoneal, intramuscular and subcutaneous routes, the intravenous route being preferred.

The administered dose of the compounds of the invention will be adapted by the practitioner according to the route of administration to the patient and the condition of said patient.

The compounds of the present invention can be administered alone or as a mixture with other anticancer agents. Among the possible combinations, mention may be made of:

- alkylating agents, and in particular cyclophosphamide, melphalan, ifosfamide, chlorambucil, busulphan, thiotepa, prednimustine, carmustin, lomustin, semustin, streptozotocin, decarbazine, temozolomide, procarbazine and hexamethylmelamine;
- platinum derivatives, such as in particular cisplatin, carboplatin or oxaliplatin;
- antibiotics, such as in particular bleomycin, mitomycin or dactinomycin;
- antimicrotubule agents, such as in particular vinblastine, vincristine,

vindesine, vinorelbine or taxoids (paclitaxel and docetaxel);

- anthracyclines, such as in particular doxorubicin, daunorubicin, idarubicin, epirubicin, mitoxantrone or losoxantrone;
- topoisomerases of groups I and II, such as etoposide, teniposide,
5 amsacrine, irinotecan, topotecan and tomudex;
- fluoropyrimidines such as 5-fluorouracil, UFT or floxuridine;
- cytidine analogues such as 5-azacytidine, cytarabine, gemcitabine, 6-mercaptopurine or 6-thioguanine;
- adenosine analogues such as pentostatin, cytarabine or fludarabine
10 phosphate;
- methotrexate and folinic acid;
- various enzymes and compounds such as L-asparaginase, hydroxyurea, trans-retinoic acid, suramine, dexrazoxane, amifostine, herceptin and also oestrogenic and androgenic hormones;
- 15 • antivascular agents, such as combretastatin derivatives for example CA4P, chalcones or colchicine, for example ZD6126, and prodrugs thereof;
- kinase inhibitors such as ertotinib or imatinib;
- biotherapeutic agents, for instance antibodies, such as rituximab, bevacizumab, cetuximab, trastuzumab or alemtuzumab;
- 20 • proteasome inhibitors such as bortezomib.

It is also possible to combine the compounds of the present invention with a radiation treatment. These treatments can be administered simultaneously, separately or sequentially. The treatment will be adapted by the practitioner according to the patient to be treated.

Definitions

The term "halogen" refers to an element selected from F, Cl, Br and I.

The term "alkyl" refers to a linear or branched, saturated hydrocarbon-based substituent containing from 1 to 12 carbon atoms. Methyl, ethyl, propyl,
5 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3,3-dimethylbutyl, heptyl, 1-ethylpentyl, octyl, nonyl, decyl, undecyl and dodecyl substituents are
10 examples of an alkyl substituent.

The term "alkenyl" refers to a linear or branched hydrocarbon-based substituent having one or more unsaturations, containing from 2 to 12 carbon atoms. Ethylenyl, 1-methylethylenyl, prop-1-enyl, prop-2-enyl, Z-1-methylprop-1-enyl, E-1-methylprop-1-enyl, Z-1,2-dimethylprop-1-enyl,
15 E-1,2-dimethylprop-1-enyl, but-1,3-dienyl, 1-methyldienylprop-2-enyl, Z-2-methylbut-1,3-dienyl, E-2-methylbut-1,3-dienyl, 2-methyl-1-methyldienylprop-2-enyl, undec-1-enyl and undec-10-enyl substituents are examples of an alkylene substituent.

The term "alkynyl" refers to a linear or branched hydrocarbon-based
20 substituent having at least two unsaturations borne by a pair of vicinal carbon atoms, and containing from 2 to 12 carbon atoms. Ethynyl, prop-1-ynyl, prop-2-ynyl and but-1-ynyl substituents are examples of an alkynyl substituent.

The term "aryl" refers to a monocyclic or polycyclic aromatic substituent containing from 6 to 14 carbon atoms. Phenyl, naphth-1-yl, naphth-2-yl,
25 anthracen-9-yl, 1,2,3,4-tetrahydronaphth-5-yl and 1,2,3,4-tetrahydronaphth-6-yl substituents are examples of an aryl substituent.

The term "heteroaryl" refers to a monocyclic or polycyclic heteroaromatic substituent containing from 1 to 13 carbon atoms and from 1 to 4 heteroatoms. Pyrrol-1-yl; pyrrol-2-yl; pyrrol-3-yl; furyl; thienyl; imidazolyl;

oxazolyl; thiazolyl; isoxazolyl; isothiazolyl; 1,2,4-triazolyl; oxadiazolyl; thiadiazolyl; tetrazolyl; pyridyl; pyrimidyl; pyrazinyl; 1,3,5-triazinyl; indolyl; benzo[b]furyl; benzo[b]thienyl; indazolyl; benzimidazolyl; azaindolyl; quinoleyl; isoquinoleyl; carbazolyl and acridyl substituents are examples of a heteroaryl substituent.

The term "heteroatom" refers herein to an atom, that is at least divalent, other than carbon. N; O; S and Se are examples of a heteroatom.

The term "cycloalkyl" refers to a saturated or partially unsaturated cyclic hydrocarbon-based substituent containing from 3 to 12 carbon atoms.

10 Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, bicyclo[2.2.1]heptyl, cyclooctyl, bicyclo[2.2.2]octyl, adamantyl and perhydronaphthyl substituents are examples of a cycloalkyl substituent.

The term "heterocyclyl" refers to a saturated or partially unsaturated, cyclic hydrocarbon-based substituent containing from 1 to 13 carbon atoms and from 1 to 4 heteroatoms. Preferably, the saturated or partially unsaturated, cyclic hydrocarbon-based substituent will be monocyclic and will contain 4 or 5 carbon atoms and 1 to 3 heteroatoms.

As regards the term "condensed phenyl", when m has the value zero, it is intended to mean that it is an unsubstituted phenyl (or substituted with 4 hydrogen atoms), and when m has the value 1, 2, 3 or 4, it is intended to mean that 1, 2, 3 or 4 hydrogen atoms are substituted with a substituent R₄.


The advantages of the invention will be more particularly illustrated by the following examples:

25 Abbreviations:


Ac acetate; **Bn** benzyl; **°C** degrees Celsius; **cat.** catalyst; **TLC** thin-layer chromatography; **PCC** preparative column chromatography; **cm** centimetre; δ chemical shift; **d** doublet; **dd** doublet of doublets; **DMF** dimethylformamide;

DMSO-d⁶ deuterated dimethyl sulphoxide; **dt** doublet of triplets; **eq.** equivalent; **ES+/-** electrospray (positive/negative modes); **Et** ethyl; **g** gram; **h** hour; **Hz** hertz; **IC₅₀** constant for 50% inhibition of activity; **iPr** isopropyl; **d** day; **J** coupling constant; **LCMS** liquid chromatography coupled to mass spectrometry; **m** multiplet; **Me** methyl; **mg** milligram; **MHz** megahertz; **ml** millilitre; **μl** microlitre; **mm** millimetre; **μm** micrometre; **mmol** millimole; **min** minute; **N** mol.L⁻¹; **Mp** melting point; **Ph** phenyl; **ppm** parts per million; **q** quadruplet; **Yld** yield; **Rf** frontal ratios; ¹**H NMR** proton nuclear magnetic resonance; **s** singlet; **bs** broad singlet; **t** triplet; **AT** ambient temperature; **tBu** tert-butyl; **TFA** trifluoroacetic acid; **THF** tetrahydrofuran; **t_R** retention time; **U.V.** ultraviolet; **V** volt.

Ex1: N-[1-(3,5-difluorobenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-((E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide



Step 1: Preparation of tert-butyl (2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)carbamate (**2**)




A solution of 2.48 g of tBoc₂O (11.4 mmol) in 50 ml of CHCl₃ is added, at 0°C, to a 250 ml round-bottomed flask containing 2.0 g of **1** (11.4 mmol) (3-amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one, commercial from Interchim), 1.15 ml of TEA (11.4 mmol) and 50 ml of CHCl₃. The medium is stirred for 2 h at 0°C under argon. The reaction medium is washed with 10 ml of HCl (1N) and 100 ml of water. The organic phase is dried over MgSO₄, filtered and evaporated to dryness. 3.75 g of a cream solid are obtained, which solid is triturated in 20 ml of isopropyl ether. After filter-drying, 2.3 g of **2** (off-white solid) are obtained.

¹H NMR (400 MHz, DMSO-d₆), δ(ppm): 1.33 (s, 9H); 2.06 (m, 1H); 2.18 (m, 1H); from 2.60 to 2.70 (m, 2H); 3.87 (m, 1H); 6.92 (d, J = 8.0 Hz, 1H); 7.00 (d, J = 7.5 Hz, 1H); 7.11 (broad t, J = 7.5 Hz, 1H); from 7.21 to 7.29 (m, 2H); 9.68 (s, 1H).

5


Step 2: Preparation of tert-butyl [1-(3,5-difluorobenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]carbamate (**3**)



72 mg of sodium hydride in suspension at 60% in oil (1.81 mmol) are introduced, at AT, into a 100 ml round-bottomed flask, with stirring and under an argon atmosphere, containing 20 ml of THF and 0.5 g of **2** (1.81 mmol). The medium is stirred for 1 h and then 0.75 g (3.62 mmol) of 3,5-difluorobenzyl bromide is added. The medium is left stirring at AT overnight. 50 ml of EtOAc are added and the organic phase is washed with 50 ml of water. The organic phase is dried over MgSO₄, filtered and then evaporated to dryness. 1 g of a white solid is obtained. After trituration with 20 ml of isopropyl ether and filter-drying, 0.62 g of product **3** (white solid) is obtained.

¹H NMR (400 MHz, DMSO-d₆), δ(ppm): 1.35 (s, 9H); 2.10 (m, 2H); 2.52 (m partially masked, 1H); 2.61 (m, 1H); 3.94 (m, 1H); 4.92 (d, J = 16.0 Hz, 1H); 5.10 (d, J = 16.0 Hz, 1H); 6.96 (m, 2H); 7.09 (tt, J = 2.5 and 9.5 Hz, 1H); from 7.17 to 7.22 (m, 3H); from 7.25 to 7.34 (m, 2H).

Step 3: Preparation of the hydrochloride of 3-amino-1-(3,5-difluorobenzyl)-1,3,4,5-tetrahydro-1-benzazepin-2-one (**4**)




25

0.62 g of **3** (1.54 mmol) are taken up in a 25 ml round-bottomed flask and

10 ml of a solution of hydrochloric acid in dioxane (4M) are added. The medium is stirred for 5 h at AT under argon. After the solvent has been evaporated off, 0.46 g of amine **4** in hydrochloride form is obtained, and is used directly for the following step.

- 5 ¹H NMR (300 MHz, DMSO-d₆), δ(ppm): 2.16 (m, 1H); 2.43 (m, 1H); 2.57 (m, 1H); 2.70 (m, 1H); 3.76 (dd, J = 7.5 and 11.5 Hz, 1H); 5.04 (d, J = 15.5 Hz, 1H); 5.12 (d, J = 15.5 Hz, 1H); 6.99 (m, 2H); 7.14 (tt, J = 2.5 and 9.5 Hz, 1H); from 7.22 to 7.40 (m, 4H); 8.31 (broad s, 3H) .

- 10 Step 4: Preparation of N-[1-(3,5-difluorobenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-2-[(4R,5S,6R)-6-((E)-3,3-dimethylbut-1-enyl)-5-hydroxy-2,2-dimethyl-1,3-dioxinan-4-yl]-2-methoxyacetamide (**6**)




- 100 mg of **5** (352 μmol) (which can be prepared according to the procedures described in Org. Process Res. Dev. 2003, 7(6), 856-865), 239 mg of **4** (0.70 mmol) and 146 mg of sodium 2-ethylhexanoate (0.77 mmol) in 2 ml of THF are introduced successively into a Wheaton tube, with agitation and under an argon atmosphere. The agitation is maintained at AT for 24 h. 3 ml of ethyl acetate are added to the reaction medium. The mixture is washed successively with 3 ml of a solution of HCl (1N), then 3 ml of a saturated solution of NaHCO₃ and 3 ml of water. The organic phase is dried over anhydrous magnesium sulphate, filtered and then evaporated to dryness. 450 mg of a colourless oil are obtained, which oil is chromatographed on a silica cartridge (20 g, eluent CH₂Cl₂/MeOH - as an MeOH gradient of 1 to 10%).
- 25 122 mg of expected product **6** are recovered.

¹H NMR (400 MHz, DMSO-d₆), δ(ppm): (a 50%-50% mixture of isomers) 0.98 (s, 4.5H); 0.99 (s, 4.5H); 1.20 (s, 1.5H); 1.21 (s, 1.5H); 1.26 (s, 1.5H); 1.27 (s, 1.5H); 2.15 (m, 2H); 2.53 (m partially masked, 1H); 2.63 (m, 1H); 3.23 (s, 1.5H); 3.25 (m masked, 1H); 3.26 (s, 1.5H); 3.75 (d, J = 8.5 Hz, 0.5H); 3.80

(d, $J = 8.5$ Hz, 0.5H); 3.91 (broad d, $J = 8.5$ Hz, 0.5H); 3.96 (broad d, $J = 8.5$ Hz, 0.5H); from 4.20 to 4.42 (m, 3H); from 4.95 to 5.11 (m, 2H); 5.44 (resolved dd, $J = 7.0$ and 16.0 Hz, 1H); 5.67 (resolved d, $J = 16.0$ Hz, 1H); 6.94 (m, 2H); 7.10 (m, 1H); from 7.18 to 7.37 (m, 4H); 8.26 (d, $J = 8.0$ Hz, 0.5H); 8.35 (d, $J = 7.0$ Hz, 0.5H).

Step 5: Preparation of N-[1-(3,5-difluorobenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-((E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide (**Ex1**)



10

92 mg of **6** (157 μ mol) in 0.8 ml of THF and 1.57 ml of 1N hydrochloric acid (1.57 mmol) are mixed in a 10 ml round-bottomed flask, with agitation and under argon. The agitation is maintained for 5 h at AT. A precipitate forms and is filter-dried over a sintered glass funnel. After washing with 0.5 ml of THF and then 2 ml of isopropyl ether and vacuum drying, 70 mg of **Ex1** (white solid) are obtained.


15

ES: $m/z = 569$ MNa^+ .


1H NMR (400 MHz, DMSO- d_6), δ (ppm): (a 50%-50% mixture of isomers) 0.94 (s, 4.5H); 0.95 (s, 4.5H); 2.18 (m, 2H); 2.53 (m partially masked, 1H); 2.63 (m, 1H); 3.22 (s, 1.5H); 3.24 (s, 1.5H); from 3.26 to 3.33 (m masked, 1H); 3.52 (m, 1H); 3.68 (d, $J = 8.0$ Hz, 1H); 3.94 (m, 1H); from 4.18 to 4.36 (m, 3H); 4.54 (broad d, $J = 4.5$ Hz, 1H); from 4.98 to 5.10 (m, 2H); 5.28 (resolved dd, $J = 7.0$ and 16.0 Hz, 1H); 5.61 (d, $J = 16.0$ Hz, 1H); 6.95 (m, 2H); 7.10 (tt, $J = 2.5$ and 10.0 Hz, 1H); from 7.17 to 7.36 (m, 4H); 8.16 (d, $J = 8.0$ Hz, 0.5H); 8.24 (d, $J = 7.0$ Hz, 0.5H).

25

Ex2: N-[1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-((E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide




Step 1: Preparation of tert-butyl [1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]carbamate (**7**)



- 5 174 mg of sodium hydride in suspension at 60% in oil (4.34 mmol) are introduced, at AT, into a 100 ml round-bottomed flask, with stirring and under an argon atmosphere, containing 50 ml of THF and 1.2 g of **2** (4.34 mmol). The medium is stirred for 1 h and then 1.23 g (8.69 mmol) of methyl iodide are added. The medium is left stirring overnight, 50 ml of EtOAc are added,
- 10 and the organic phase is washed with 100 ml of water. The organic phase is dried over MgSO_4 , filtered and then evaporated to dryness. 1.3 g of a white solid are obtained. After chromatography on a silica cartridge (40 g) (eluent $\text{CH}_2\text{Cl}_2/\text{MeOH}$ - as an MeOH gradient of 1 to 10%). 0.66 g of product **7** (white solid) is obtained.
- 15 ^1H NMR (400 MHz, DMSO-d_6), $\delta(\text{ppm})$: 1.33 (s, 9H); 2.05 (m, 2H); 2.62 (m, 2H); 3.26 (s, 3H); 3.86 (m, 1H); 7.00 (d, $J = 8.5$ Hz, 1H); 7.21 (m, 1H); 7.28 (m, 1H); 7.36 (m, 2H).

Step 2: Preparation of the hydrochloride of 3-amino-1-methyl-1,3,4,5-tetrahydro-1-benzazepin-2-one (**8**)

20




- 0.66 g of **7** (2.27 mmol) is taken up in a 50 ml round-bottomed flask and 15 ml of a solution of hydrochloric acid in dioxane (4M) are added. The mixture is stirred for 5 h at AT under argon. After the solvent has been evaporated off,
- 25 0.53 g of amine **8** in hydrochloride form is obtained, and is used directly for

the following step.

¹H NMR (300 MHz, DMSO-d₆), δ(ppm): 2.12 (m, 1H); 2.45 (m partially masked, 1H); from 2.68 to 2.79 (m, 2H); 3.34 (s, 3H); 3.59 (dd, J = 7.5 and 11.5 Hz, 1H); 7.25 (m, 1H); 7.35 (broad d, J = 7.5 Hz, 1H); 7.40 (m, 2H); 8.38 (broad s, 3H).

Step 3: Preparation of (3R,4R,5S)-4-hydroxy-5-((E)-(R)-1-hydroxy-4,4-dimethylpent-2-enyl)-3-methoxydihydrofuran-2-one (**9**)



17 ml of TFA in 10 ml of water are added to a 250 ml round-bottomed flask containing 40 ml of water and 3.6 g of **3** in suspension. The medium is stirred for 1.5 h at AT. The medium is diluted with 290 ml of water, frozen and then lyophilized. 4 g of an oil are obtained, which oil is crystallized from 20 ml of isopropyl ether at AT. After filter-drying, washing with isopropyl ether and vacuum drying at 40°C, 2.46 g of expected product **9** (white crystals) are obtained.


Mp: 123°C.

IC: m/z = 262 MNH₄⁺.

¹H NMR (400 MHz, DMSO-d₆), δ(ppm): 1.00 (s, 9H); 3.41 (s, 3H); 3.93 (dd, J = 2.5 and 9.0 Hz, 1H); from 4.22 to 4.31 (m, 3H); 5.19 (d, J = 5.0 Hz, 1H); 5.42 (dd, J = 5.0 and 16.0 Hz, 1H); 5.43 (d, J = 4.5 Hz, 1H); 5.87 (d, J = 16.0 Hz, 1H).

IR (KBr): 3239; 2964; 2914; 1701; 1499; 1312; 1253; 1047 & 751 cm⁻¹.

Step 4: Preparation of N-[1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-((E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide (**Ex2**)




36 mg of **9** (147 μ mol), 66.8 mg of **8** (0.30 mmol), 61 mg of sodium 2-ethylhexanoate (0.37 mmol) in 1.0 ml of THF are successively introduced into a Wheaton tube, with agitation and under an argon atmosphere. The agitation is maintained at AT for 24 h. The reaction medium is directly evaporated to dryness. The crude is chromatographed on a silica cartridge (5 g, eluent $\text{CH}_2\text{Cl}_2/\text{MeOH}$ - as an MeOH gradient of 1 to 10%). 39 mg of expected product **Ex2** are recovered.


ES: $m/z = 457 \text{ MNa}^+$; $m/z = 435 \text{ MH}^+$.

- ¹H NMR (400 MHz, DMSO- d_6), δ (ppm): (a 50%-50% mixture of isomers) 0.95 (s, 4.5H); 0.96 (s, 4.5H); 2.06 (m, 1H); 2.21 (m, 1H); from 2.60 to 2.75 (m, 2H); 3.21 (s, 3H); from 3.25 to 3.35 (m masked, 1H); 3.29 (broad s, 3H); 3.51 (broad m, 1H); 3.66 (d, $J = 7.5 \text{ Hz}$, 0.5H); 3.67 (d, $J = 7.5 \text{ Hz}$, 0.5H); 3.93 (m, 1H); 4.21 (m, 1H); from 4.28 to 4.60 (broad m, 3H); 5.28 (dd, $J = 7.0$ and 16.0 Hz, 0.5H); 5.30 (dd, $J = 7.0$ and 16.0 Hz, 0.5H); 5.61 (d, $J = 16.0 \text{ Hz}$, 0.5H); 5.63 (d, $J = 16.0 \text{ Hz}$, 0.5H); 7.22 (m, 1H); 7.31 (m, 1H); from 7.37 (m, 2H); 8.03 (d, $J = 8.0 \text{ Hz}$, 0.5H); 8.05 (d, $J = 7.0 \text{ Hz}$, 0.5H).

Ex3: N-(7-bromo-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide and **Ex3a** & **Ex3b**




Step 1: Preparation of tert-butyl (7-bromo-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)carbamate (**10**)



472 mg of N-bromosuccinimide (2.65 mmol) are introduced at AT into a 100 ml round-bottomed flask, with stirring and under an argon atmosphere, containing 40 ml of EtOAc and 0.5 g of **2** (1.8 mmol). The medium is left stirring overnight, and is washed with 40 ml of HCl (1N), 40 ml of saturated aqueous solution of NaHCO₃ and 40 ml of water. The organic phase is dried over MgSO₄, filtered and then evaporated to dryness. 1.3 g of an oil are obtained, which oil is crystallized from 10 ml of isopropyl ether. After filter-drying, 450 mg of product **10** (white solid) are obtained.

¹H NMR (400 MHz, DMSO-d₆), δ(ppm): 1.34 (s, 9H); 2.05 (m, 1H); 2.21 (m, 1H); from 2.58 to 2.72 (m, 2H); 3.86 (m, 1H); 6.95 (d, J = 8.5 Hz, 1H); 6.98 (d, J = 8.5 Hz, 1H); 7.44 (dd, J = 2.0 and 8.5 Hz, 1H); 7.50 (d, J = 2.0 Hz, 1H); 9.7 (s, 1H).


Step 2: Preparation of the hydrochloride of 3-amino-7-bromo-1,3,4,5-tetrahydro-1-benzazepin-2-one (**11**)



0.45 g of **10** (1.27 mmol) are taken up in a 25 ml round-bottomed flask and 10 ml of a solution of hydrochloric acid in dioxane (4M) are added. The medium is stirred for 5 h at AT under argon. A precipitate forms, and is filtered over a sintered glass funnel, and washed with 5 ml of dioxane and then 5 ml of isopropyl ether. 0.38 g of amine **11** in hydrochloride form is obtained.

¹H NMR (400 MHz, DMSO-d₆), δ(ppm): 2.12 (m, 1H); 2.51 (m partially masked, 1H); from 2.65 to 2.84 (m, 2H); 3.72 (dd, J = 8.0 and 11.5 Hz, 1H); 6.99 (d, J = 8.5 Hz, 1H); 7.48 (dd, J = 2.5 and 8.5 Hz, 1H); 7.58 (d, J = 2.5 Hz, 1H); 8.25 (s, 3H); 10.35 (s, 1H).

Step 3: Preparation of (R)-N-(7-bromo-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)-2-[(4R,5S,6R)-6-((E)-3,3-dimethylbut-1-enyl)-5-hydroxy-2,2-dimethyl-1,3-dioxinan-4-yl]-2-methoxyacetamide (**12**)




- 5 100 mg of **5** (352 μ mol), 205 mg of **11** (0.70 mmol) and 146 mg of sodium 2-ethylhexanoate (0.77 mmol) in 2 ml of THF are successively introduced into a Wheaton tube, with agitation and under an argon atmosphere. The agitation is maintained at AT for 24 h. The medium is evaporated to dryness and then purified by chromatography on a silica cartridge (20 g) with an eluent of
- 10 $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (as an MeOH gradient of 1 to 10%). 160 mg of expected product **12** are recovered.

^1H NMR (300 MHz, $\text{DMSO}-d_6$), δ (ppm): (a 70%-30% mixture of isomers) 0.99 (s, 9H); 1.23 (s, 0.9H); 1.25 (s, 2.1H); 1.28 (s, 0.9H); 1.29 (s, 2.1H); 2.08 (m, 1H); 2.27 (m, 1H); from 2.65 to 2.76 (m, 2H); from 3.21 to 3.34 (m masked, 1H); 3.24 (s, 2.1H); 3.26 (s, 0.9H); 3.73 (d, $J = 8.5$ Hz, 0.7H); 3.78 (d, $J = 8.5$ Hz, 0.3H); 3.90 (broad d, $J = 8.5$ Hz, 0.3H); 3.96 (broad d, $J = 8.5$ Hz, 0.7H); from 4.12 to 4.43 (m, 3H); 5.43 (dd, $J = 7.0$ and 16.0 Hz, 0.3H); 5.44 (dd, $J = 7.0$ and 16.0 Hz, 0.7H); 5.68 (broad d, $J = 16.0$ Hz, 1H); 6.97 (d, $J = 8.5$ Hz, 1H); 7.46 (dd, $J = 2.5$ and 8.5 Hz, 1H); 7.54 (d, $J = 2.5$ Hz, 1H); 8.08 (d, $J = 8.0$ Hz, 0.7H); 8.15 (d, $J = 7.5$ Hz, 0.3H); 9.85 (s, 0.3H); 9.89 (s, 0.7H).

15

20

Step 4: Preparation of N-(7-bromo-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide (**Ex3**) and **Ex3a** & **Ex3b**



25

150 mg of **12** (258 μ mol) in 1.4 ml of THF and 2.78 ml of 1N hydrochloric acid

are introduced into a 25 ml round-bottomed flask, with agitation and under argon. The agitation is maintained for 4.5 h at AT. The medium is neutralized with NaOH (1N), to pH 7, and extracted with 2 times 3 ml of EtOAc. The combined organic phases are dried over MgSO₄, filtered and evaporated to dryness. The crude is chromatographed on a silica cartridge (10 g), elution being carried out with CH₂Cl₂/MeOH (*as an MeOH gradient of 1 to 10%*). 65 mg of expected product **Ex3** are recovered. 40 mg of **Ex3** are separated by preparative chiral HPLC (Chirapad AD-H 5 μ m 250 $\times$ 4.6 mm, flow rate 1 ml/min, mobile phase: 50% heptane-50% EtOH, 0.1% TEA), to give 9 mg of **Ex3a** (tr = 7.48 min) and 20 mg of **Ex3b** (tr = 9.71 min).


ES: m/z = 497 (M-H)⁻.

Ex3: ¹H NMR (400 MHz, DMSO-d₆), δ (ppm): (a 70%-30% mixture of isomers) 0.95 (s, 6.3 H); 0.96 (s, 2.7H); 2.09 (m, 1H); 2.31 (m, 1H); from 2.65 to 2.73 (m, 2H); from 3.19 to 3.33 (m masked, 1H); 3.22 (s, 2.1H); 3.29 (s, 0.9H); 3.52 (m, 1H); 3.66 (d, J = 8.0 Hz, 0.3H); 3.68 (d, J = 7.5 Hz, 0.7H); 3.94 (m, 1H); from 4.16 to 4.41 (m, 3H); 4.55 (d, J = 4.5 Hz, 1H); 5.28 (dd, J = 7.0 and 16.0 Hz, 0.3H); 5.30 (dd, J = 7.0 and 16.0 Hz, 0.7H); 5.61 (d, J = 16.0 Hz, 0.3H); 5.63 (d, J = 16.0 Hz, 0.7H); 6.97 (d, J = 8.5 Hz, 1H); 7.46 (dd, J = 2.5 and 8.5 Hz, 1H); 7.54 (d, J = 2.5 Hz, 1H); 8.04 (d, J = 7.5 Hz, 1H); 9.91 (s, 0.3H); 9.95 (s, 0.7H) .


Ex3a: ¹H NMR (400 MHz, DMSO-d₆), δ (ppm): 0.96 (s, 9H); 2.07 (m, 1H); 2.30 (m, 1H); 2.70 (m, 2H); 3.22 (s, 3H); from 3.27 to 3.35 (m masked, 1H); 3.51 (m, 1H); 3.67 (d, J = 7.5 Hz, 1H); 3.91 (m, 1H); 4.19 (m, 1H); 4.29 (m, 2H); 4.54 (d, J = 4.5 Hz, 1H); 5.29 (dd, J = 7.0 and 16.0 Hz, 1H); 5.62 (d, J = 16.0 Hz, 1H); 6.97 (d, J = 8.5 Hz, 1H); 7.45 (dd, J = 2.5 and 8.5 Hz, 1H); 7.54 (d, J = 2.5 Hz, 1H); 8.02 (d, J = 7.5 Hz, 1H); 9.90 (s, 1H).

Ex4: N-(7-phenyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide and

Ex4a & Ex4b




Step 1: Preparation of tert-butyl (7-phenyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)carbamate (**13**)



371 mg of phenylboronic acid (3.04 mmol), 62 mg of 1,1'-bis(diphenylphosphino)ferrocene palladium chloride ($C_{35}H_{30}Cl_4FeP_2Pd$, Mw 816.65, 0.025 mmol) and 3.96 g of caesium carbonate (12.16 mmol) are introduced into a 100 ml round-bottomed flask, with stirring and under an argon atmosphere, containing 22 ml of water, 6.5 ml of dioxane and 1.08 g of **10** (3.04 mmol). The medium is heated at 100°C, with stirring, for 1 h. The medium is filtered over celite and washed with 10 ml of dioxane, 10 ml of CH_2Cl_2 and 10 ml of MeOH. The filtrate is concentrated under vacuum. 25 ml of EtOAc are then added and the mixture is washed with 2 times 25 ml of water. The organic phase is dried over $MgSO_4$, filtered and evaporated to dryness. The crude is chromatographed on a silica cartridge (50 g), elution being carried out with $CH_2Cl_2/MeOH$ (as an MeOH gradient: 1 to 10%). 350 mg of expected product **13** (white solid) are recovered.

1H NMR (300 MHz, $DMSO-d_6$), δ (ppm): 1.34 (s, 9H); 2.09 (m, 1H); 2.25 (m, 1H); from 2.63 to 2.79 (m, 2H); 3.94 (m, 1H); 6.97 (d, $J = 8.5$ Hz, 1H); 7.09 (d, $J = 8.5$ Hz, 1H); 7.34 (t, $J = 7.5$ Hz, 1H); 7.46 (t, $J = 7.5$ Hz, 2H); 7.56 (dd, $J = 2.0$ and 8.5 Hz, 1H); 7.58 (broad s, 1H); 7.66 (d, $J = 7.5$ Hz, 2H); 9.77 (s, 1H).


Step 2: Preparation of the hydrochloride of 3-amino-7-phenyl-1,3,4,5-tetrahydro-1-benzazapin-2-one (**14**)



0.35 g of **13** (0.99 mmol) is taken up in a 20 ml round-bottomed flask and 5 ml of a solution of hydrochloric acid in dioxane (4M) are added. The medium is stirred for 5 h at AT under argon. A precipitate forms and is filter-dried and washed with 5 ml of dioxane and then 5 ml of isopropyl ether. After drying, 0.23 g of amine **14** in hydrochloride form is obtained.

^1H NMR (400 MHz, DMSO- d_6), δ (ppm): 2.18 (m, 1H); 2.55 (m partially masked, 1H); from 2.74 to 2.90 (m, 2H); 3.76 (dd, $J = 8.5$ and 12.0 Hz, 1H); 7.12 (d, $J = 8.0$ Hz, 1H); 7.36 (t, $J = 7.5$ Hz, 1H); 7.47 (t, $J = 7.5$ Hz, 2H); 7.60 (dd, $J = 2.0$ and 8.0 Hz, 1H); from 7.64 to 7.69 (m, 3H); 8.19 (broad s, 3H); 10.35 (s, 1H).

Step 3: Preparation of (R)-N-(7-phenyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)-2-[(4R,5S,6R)-6-((E)-3,3-dimethylbut-1-enyl)-5-hydroxy-2,2-dimethyl-1,3-dioxinan-4-yl]-2-methoxyacetamide (**15**)




100 mg of **5** (352 μmol), 203 mg of **14** (0.70 mmol) and 146 mg of sodium 2-ethylhexanoate (0.77 mmol) in 2 ml of THF are successively introduced into a Wheaton tube, with agitation and under an argon atmosphere. The agitation is maintained at AT for 24 h. The mixture is evaporated to dryness and then purified by chromatography on a silica cartridge (20 g), elution being carried out with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (as an MeOH gradient: 1 to 10%). 150 mg of expected product **15** are recovered.

^1H NMR (300 MHz, DMSO- d_6), δ (ppm): (a 60%-40% mixture of isomers): 0.99 (s, 9H); 1.23 (s, 1.2H); 1.25 (s, 1.8H); 1.28 (s, 1.2H); 1.30 (s, 1.8H); 2.11 (m,

1H); 2.32 (m, 1H); 2.78 (m, 2H); from 3.22 to 3.35 (m masked, 1H); 3.25 (s, 1.8H); 3.27 (s, 1.2H); 3.74 (d, J = 8.5 Hz, 0.6H); 3.77 (d, J = 8.5 Hz, 0.4H); 3.91 (broad d, J = 8.5 Hz, 0.4H); 3.96 (broad d, J = 8.5 Hz, 0.6H); from 4.20 to 4.44 (m, 3H); 5.44 (dd, J = 7.0 and 16.0 Hz, 1H); 5.68 (d, J = 16.0 Hz, 1H); 7.10 (d, J = 8.5 Hz, 1H); 7.35 (t, J = 7.5 Hz, 1H); 7.46 (t, J = 7.5 Hz, 2H); 7.57 (broad d, J = 8.5 Hz, 1H); 7.62 (broad s, 1H); 7.67 (d, J = 7.5 Hz, 2H); 8.09 (d, J = 7.5 Hz, 0.6H); 8.15 (d, J = 7.5 Hz, 0.4H); 9.87 (s, 0.4H); 9.92 (s, 0.6H).

Step 4: Preparation of N-(7-phenyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide (**Ex4**) and **Ex4a** & **Ex4b**



150 mg of **15** (280 μ mol) in 1.4 ml of THF and 2.78 ml of 1N hydrochloric acid are introduced into a 20 ml round-bottomed flask, with stirring and under argon. The stirring is maintained for 4 h at AT. The medium is neutralized with NaOH (1N), to pH 7, and extracted with 2 times 5 ml of EtOAc. The combined organic phases are dried over MgSO_4 , filtered and evaporated to dryness. The crude is chromatographed on a silica cartridge (10 g) with an eluent of $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (as an MeOH gradient of 1 to 10%). 85 mg of expected product **Ex4** are recovered. 58 mg of **Ex4** are separated by preparative chiral HPLC (Chirapad AD-H 5 μ m 250 $\times$ 4.6 mm, flow rate 1 ml/min, mobile phase: 70% heptane-30% EtOH, 0.1% TEA), to give 16 mg of **Ex4a** (tr = 13.42 min) and 40 mg of **Ex4b** (tr = 18.96 min).


ES: 497 MH^+ .

Ex4: ^1H NMR (400 MHz, DMSO-d_6), δ (ppm): (a 70%-30% mixture of isomers) 0.95 (s, 2.7H); 0.99 (s, 6.3H); 2.11 (m, 1H); 2.35 (m, 1H); 2.79 (m, 2H); 3.23 (s, 3H); from 3.25 to 3.35 (m masked, 1H); 3.53 (m, 1H); 3.68 (d, J = 8.5 Hz, 0.3H); 3.70 (d, J = 8.5 Hz, 0.7H); 3.95 (m, 1H); from 4.22 to 4.33 (m, 2.3H);


4.41 (d, $J = 6.0$ Hz, 0.7H); 4.55 (m, 1H); 5.30 (m, 1H); 5.61 (d, $J = 16.0$ Hz, 0.3H); 5.63 (d, $J = 16.0$ Hz, 0.7H); 7.10 (d, $J = 8.5$ Hz, 1H); 7.35 (t, $J = 7.5$ Hz, 1H); 7.46 (t, $J = 8.0$ Hz, 2H); 7.57 (dd, $J = 2.5$ and 8.5 Hz, 1H); 7.62 (broad s, 1H); 7.67 (d, $J = 8.0$ Hz, 2H); 8.04 (d, $J = 7.5$ Hz, 1H); 9.93 (s, 0.3H); 9.99 (s, 0.7H).

Ex4a: ^1H NMR (400 MHz, DMSO- d_6), δ (ppm): 0.95 (s, 9H); 2.10 (m, 1H); 2.37 (m, 1H); 2.79 (m, 2H); 3.24 (s, 3H); from 3.27 to 3.33 (m masked, 1H); 3.51 (m, 1H); 3.68 (d, $J = 7.5$ Hz, 1H); 3.93 (m, 1H); from 4.22 to 4.32 (m, 3H); 4.54 (d, $J = 4.5$ Hz, 1H); 5.29 (dd, $J = 7.0$ and 16.0 Hz, 1H); 5.61 (d, $J = 16.0$ Hz, 1H); 7.10 (d, $J = 8.0$ Hz, 1H); 7.35 (t, $J = 7.5$ Hz, 1H); 7.46 (t, $J = 7.5$ Hz, 2H); 7.56 (dd, $J = 2.0$ and 8.0 Hz, 1H); 7.62 (d, $J = 2.0$ Hz, 1H); 7.67 (m, 2H); 8.02 (d, $J = 7.5$ Hz, 1H); 9.93 (s, 1H).

Ex4a: (2*R*,3*R*,4*S*,5*R*,6*E*)-3,4,5-trihydroxy-2-methoxy-8,8-dimethyl-*N*-[(3*S*)-2-oxo-7-phenyl-2,3,4,5-tetrahydro-1*H*-1-benzazepin-3-yl]non-6-enamide



Step 1: Preparation of *tert*-butyl [(3*S*)-2-oxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-3-yl]carbamate (**2a**)




16 ml of TEA (113.5 mmol), and a solution of 24.77 g of $t\text{Boc}_2\text{O}$ (113.5 mmol) in 500 ml of CHCl_3 are added at 0°C to a 2 l round-bottomed flask containing 20.0 g of **1a** (113.5 mmol) ((*s*)-3-amino-1,3,4,5-tetrahydro-2*H*-1-benzazepin-2-one, prepared according to the procedures described in J. Org. Chem. 1997, 62, 8271), and 500 ml of CHCl_3 . The medium is stirred overnight. The reaction medium is washed with 500 ml of HCl (0.5N) and 500 ml of water.

The organic phase is dried over MgSO_4 , filtered and evaporated to dryness, and the solids are disintegrated with 200 ml of isopropyl ether. After filter-drying, 30.02 g of **2a** (off-white solid) are obtained.

$[\alpha]_D$: -229.0 $\pm$ 2.5 ($c=1.852$ mg/0.5 ml MeOH)

- 5 ^1H NMR (400 MHz, $\text{DMSO}-d_6$), δ (ppm): 1.33 (s, 9H); from 1.98 to 2.25 (m, 2H); from 2.59 to 2.71 (m, 2H); 3.89 (m, 1H); 6.90 (d, $J = 8.0$ Hz, 1H); 7.00 (d, $J = 7.5$ Hz, 1H); 7.11 (d, $J = 7.5$ Hz, 1H); from 7.20 to 7.30 (m, 2H); 9.68 (s, 1H).


- 10 Step 2: Preparation of *tert*-butyl [(3*S*)-7-bromo-2-oxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-3-yl]carbamate (**10a**)



- 23.5 g of N-bromosuccinimide (136 mmol) are introduced, at AT, as 4 portions over 3 days, into a 2 l three-necked flask, with stirring and under an argon atmosphere, containing 1.5 l of EtOAc and 8.47 g of **2a** (103.0 mmol). The medium is left stirring for an additional overnight period, and washed with 500 ml of HCl (0.5N), 500 ml of a saturated aqueous solution of NaHCO_3 and 500 ml of water. The organic phase is dried over MgSO_4 , filtered and then evaporated to dryness. 38 g of brown foam are obtained. The product is purified by chromatography on a silica cartridge (600 g), elution being carried out with heptane/EtOAc (70/30). 20.46 g of expected product **10a** (white solid) are recovered.

- 25 ^1H NMR (400 MHz, $\text{DMSO}-d_6$), δ (ppm): 1.34 (s, 9H); 2.05 (m, 1H); 2.20 (m, 1H); from 2.56 to 2.73 (m, 2H); 3.87 (m, 1H); 6.97 (m, 2H); 7.45 (dd, $J = 2.0$ and 8.0 Hz, 1H); 7.51 (d, $J = 2.0$ Hz, 1H); 9.75 (s, 1H).

Step 3: Preparation of *tert*-butyl [(3*S*)-2-oxo-7-phenyl-2,3,4,5-tetrahydro-1*H*-1-benzazepin-3-yl]carbamate (**13a**)



2.643 g of phenylboronic acid (21.68 mmol), 402 mg of 1,1'-bis(diphenylphosphino)ferrocene palladium chloride ($C_{35}H_{30}Cl_4FeP_2Pd$, Mw 816.65, 0.493 mmol) and 25.69 g of caesium carbonate (78.84 mmol) are introduced into a 500 ml round-bottomed flask, with stirring and under an argon atmosphere, containing 142 ml of water, 42 ml of dioxane and 7.0 g of **10a** (19.71 mmol). The medium is heated at 100°C with stirring for 4 h. The dioxane is concentrated under vacuum, 100 ml of distilled water are added, and the mixture is extracted with 2 × 200 ml of EtOAc. The organic phase is dried over $MgSO_4$, filtered and evaporated to dryness. 7 g of a brown solid are obtained, which solid is crystallized from 55 ml of toluene under hot conditions. After having left the product to stand at AT overnight, the needles are filter-dried, and washed with 5 ml of toluene and with 5 ml of isopropyl ether. After vacuum drying, 5.63 g of expected product **13a** are obtained.


Mp = 198.6 +/- 1°C

$[\alpha]_D$: -157.0 +/- 2.1 (c = 2.332 mg/0.5 ml MeOH)

MS: m/z = 353 $[M+H]^+$

1H NMR (400 MHz, DMSO- d_6), δ (ppm): 1.34 (s, 9H); 2.09 (m, 1H); 2.25 (m, 1H); from 2.65 to 2.80 (m, 2H); 3.94 (m, 1H); 6.95 (d, J = 8.0 Hz, 1H); 7.09 (d, J = 8.5 Hz, 1H); 7.35 (t, J = 7.5 Hz, 1H); 7.46 (t, J = 7.5 Hz, 2H); 7.54 (dd, J = 2.0 and 8.5 Hz, 1H); 7.59 (d, J = 2.0 Hz, 1H); 7.67 (d, J = 7.5 Hz, 2H); 9.76 (s, 1H).

Step 3: Preparation of (3S)-3-amino-7-phenyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one hydrochloride (**14a**)




5.63 g of **13a** (15.97 mmol) are taken up in a 250 ml round-bottomed flask and 140 ml of a solution of hydrochloric acid in dioxane (4M) are added. The medium is stirred for 4 h at AT under argon. A precipitate forms and is filter-dried and washed with 5 ml of dioxane and then 5 ml of isopropyl ether. After
5 drying, 5.7 g of amine **14a** in hydrochloride form are obtained.

Mp = 198.6 +/- 1°C

$[\alpha]_D$: -292.0 +/- 3.2 (c = 1.894 mg/0.5 ml MeOH)

¹H NMR (400 MHz, DMSO-d₆), δ(ppm): 2.19 (m, 1H); 2.57 (m, 1H); from 2.72 to 2.91 (m, 2H); 3.78 (m, 1H); 7.13 (d, J = 8.5 Hz, 1H); 7.38 (t, J = 7.5 Hz,
10 1H); 7.48 (t, J = 7.5 Hz, 2H); 7.60 (dd, J = 2.0 and 8.5 Hz, 1H); 7.69 (m, 3H); 8.29 (broad s, 3H); 10.35 (s, 1H).

Step 4: Preparation of (2*R*,3*R*,4*S*,5*R*,6*E*)-3,4,5-trihydroxy-2-methoxy-8,8-dimethyl-*N*-[(3*S*)-2-oxo-7-phenyl-2,3,4,5-tetrahydro-1*H*-1-benzazepin-
15 3-yl]non-6-enamide (**Ex4a**)



2.3 g of **9** (9.42 mmol), 2.72 g of **14a** (9.42 mmol) and 3.63 g of sodium 2-ethylhexanoate (21.84 mmol) in 50.0 ml of THF are successively introduced into a 150 ml round-bottomed flask, with stirring and under an argon
20 atmosphere. The stirring is maintained at AT for 48 h. The reaction medium is directly evaporated to dryness. The crude is chromatographed on a silica cartridge (300 g, eluent EtOAc), and 3.7 g of a white solid are obtained, which solid is repurified on a silica cartridge (240 g, eluent CH₂Cl₂/MeOH - as an
MeOH gradient: 1 to 5%). 3.23 g of expected product **Ex4a** (white solid) are
25 recovered.


$[\alpha]_D$: -54.6 +/- 0.9 (c = 2.989 mg/0.5 ml MeOH)

MS: m/z = 497 [M+H]⁺


¹H NMR (400 MHz, DMSO-d₆), δ(ppm): 0.95 (s, 9H); 2.11 (m, 1H); 2.38 (m, 1H); 2.79 (m, 2H); 3.24 (s, 3H); 3.30 (m masked, 1H); 3.52 (m, 1H); 3.69 (d, J

= 8.0 Hz, 1H); 3.93 (m, 1H); from 4.20 to 4.32 (m, 3H); 4.53 (d, J = 5.5 Hz, 1H); 5.30 (dd, J = 7.5 and 16.0 Hz, 1H); 5.62 (d, J = 16.0 Hz, 1H); 7.10 (d, J = 8.5 Hz, 1H); 7.35 (t, J = 7.5 Hz, 1H); 7.45 (t, J = 7.5 Hz, 2H); 7.57 (dd, J = 2.0 and 8.5 Hz, 1H); 7.62 (d, J = 2.0 Hz, 1H); 7.68 (d, J = 7.5 Hz, 2H); 8.02 (d, J = 8.0 Hz, 1H); 9.92 (s, 1H).

Ex5: (2*R*,3*R*,4*S*,5*R*,6*E*)-7-cyclopentyl-3,4,5-trihydroxy-2-methoxy-*N*-[(3*S*)-2-oxo-7-phenyl-2,3,4,5-tetrahydro-1*H*-1-benzazepin-3-yl]hept-6-enamide




Step 1: Preparation of (4*R*,4*aS*,7*R*,7*aR*)-7-methoxy-2,2-dimethyl-4-vinyl-tetrahydro-6*H*-furo[3,2-*d*][1,3]dioxin-6-one (**17**)



A 4000 ml round-bottomed flask, equipped with a mechanical stirrer, is filled, under nitrogen, with 178.2 g of PPh₃ (0.679 mol), 84.1 g of imidazole (1.235 mol) and 2430 ml of anhydrous THF. 156.8 g of doubly sublimed iodine (0.618 mol) are carefully added while maintaining the temperature of the reaction mixture at 30°C. This medium is brought to reflux (66°C) for 1 h, and then 81 g of **16** (0.309 mol) (which can be prepared according to the procedures described in Org. Process Res. Dev. 2003, 7(6), 856-865) are gradually added at 66°C +/- 2°C. The homogeneous mixture thus obtained is refluxed for 3 h. It is allowed to return to 20°C +/- 5°C, and then 1000 ml of a 10% NaHCO₃ solution (effervescence, athermic) (pH 8.0-8.5) are run in. 185.5 g of Na₂S₂O₃ are subsequently added until almost complete discoloration is obtained (appearance of a mineral precipitate). After stirring at 20°C +/- 5°C for 30 minutes, the solid is filtered off and rinsed with THF. The

THF/H₂O filtrate is partially concentrated in a rotary evaporator at a temperature below 35°C. The aqueous concentrate is saturated with NaCl and extracted with 1500 ml of CH₂Cl₂. The organic phase is dried over MgSO₄, filtered and evaporated to dryness. The residue is taken up in 2000 ml of a mixture of H₂O/acetone (75/25), the insoluble materials are filtered off and rinsed with a the mixture of H₂O/acetone (75/25). The filtrates are concentrated in a rotary evaporator at 50°C and 20 mbar, and filtered again over a sintered glass funnel (porosity No. 4). The aqueous phase is saturated with NaCl and is extracted 3 times with CH₂Cl₂ (1000 ml, 500 ml and 250 ml). The organic phases are combined, dried over MgSO₄, filtered and evaporated to dryness, to give 60 g of crude product, which is dissolved in 250 ml de CH₂Cl₂. 30 g of silica are then added to the solution. After stirring for 15 minutes, the silica is filtered off, and rinsing is performed twice with CH₂Cl₂ (250 ml and 100 ml). The filtrate is concentrated to dryness and dried under 1 mbar at 20°C, to give 54.8 g of expected product **17** (white solid).
¹H NMR (300 MHz, DMSO-d₆), δ(ppm): 5.85 (m, 1H); 5.35 (d, 1H); 5.25 (d, 1H); 4.80 (m, 1H); 4.69 (m, 1H); 4.43 (d, 1H); 4.22 (m, 1H); 3.40 (s, 3H); 1.49 (s, 3H); 1.30 (s, 3H).

Step 2: Preparation of (3*R*,4*R*,5*S*)-4-hydroxy-5-[(1*R*)-1-hydroxyprop-2-en-1-yl]-3-methoxydihydrofuran-2(3*H*)-one (**18**)




10 ml of TFA are added dropwise, at 0°C, to a 100 ml round-bottomed flask containing 1.0 g of **17** (4.38 mmol), 10 ml of water and 14 ml of THF. The medium is left to return to AT and stirred overnight. The medium is then concentrated at reduced pressure, at AT, and 50 ml of water are added, and the mixture is frozen and lyophilized. The lyophilizate is made into a paste in heptane, in the presence of a minimum amount of methanol, after the solvents have been evaporated off. 778 mg of expected product **18** (white

solid) are obtained.

MS: $m/z = 211 [M+Na]^+$, $189 [M+H]^+$

1H NMR (400 MHz, DMSO- d_6), δ (ppm): 3.42 (s, 3H); 3.98 (dd, $J = 2.5$ and 9.0 Hz, 1H); from 4.25 to 4.34 (m, 3H); 5.22 (dm, $J = 10.5$ Hz, 1H); 5.29 (d, $J = 5.0$ Hz, 1H); 5.44 (d partially masked, $J = 16.5$ Hz, 1H); 5.46 (m, 1H); 5.97 (m, 1H).

Step 3: Preparation of (3*R*,4*R*,5*S*)-5-[(1*R*,2*E*)-3-cyclopentyl-1-hydroxyprop-2-en-1-yl]-4-hydroxy-3-methoxydihydrofuran-2(3*H*)-one (**19**)



10

100 mg (0.53 mmol) of **18**, 4 ml of CH_2Cl_2 , 726 μ l (5.3 mmol) of vinylcyclopentane and then 90.2 mg (106 μ mol) of second-generation Grubbs catalyst are introduced into a 5 ml vial. The solution is microwave-heated at 60°C for 10 min. The solvent is subsequently evaporated to dryness under reduced pressure and the residue is then purified on a Biotage 12-M silica column (eluent: 40/60 Hept/EtOAc). The product **19** (76.3 mg, $R_f = 0.35$ under the elution conditions used) is obtained in the form of a brown solid.

15


MS: $m/z = 279 [M+Na]^+$, $257 [M+H]^+$

1H NMR (300 MHz, DMSO- d_6), δ (ppm): 5.82 (dd, 1H, $J=8$ Hz and 16 Hz), 5.50 (dd, 1H, $J = 6$ Hz and 16 Hz), 5.39 (d, 1H, $J = 4.5$ Hz), 5.15 (d, 1H, $J = 6$ Hz), 4.27 (m, 3H), 3.95 (dd, 1H, $J = 3$ Hz and 8 Hz), 3.41 (s, 3H), 2.43 (m, 1H), 1.73 (m, 2H), 1.56 (m, 4H), 1.26 (m, 2H).

20

Step 4: Preparation of (2*R*,3*R*,4*S*,5*R*,6*E*)-7-cyclopentyl-3,4,5-trihydroxy-2-methoxy-*N*-[(3*S*)-2-oxo-7-phenyl-2,3,4,5-tetrahydro-1*H*-1-benzazepin-3-yl]hept-6-enamide (**Ex5**)

25




100 mg of **19** (0.39 mmol), 112.6 mg of **14a** (0.39 mmol) and 162 mg of sodium 2-ethylhexanoate (0.98 mmol) in 2.0 ml of THF are successively introduced into a Wheaton tube, with agitation and under an argon atmosphere. The agitation is maintained at AT for 24 h. The reaction medium is directly evaporated to dryness. The crude is chromatographed on a silica cartridge (12 g, eluent EtOAc). 92 mg of expected product **Ex5** (white solid) are obtained.

ES: $m/z = 531 \text{ MNa}^+$; $m/z = 509 \text{ MH}^+$.


^1H NMR (400 MHz, DMSO- d_6), δ (ppm): from 1.13 to 1.73 (m, 8H); 2.11 (m, 1H); from 2.29 to 2.45 (m, 2H); from 2.70 to 2.85 (m, 2H); 3.23 (s, 3H); 3.30 (m masked, 1H); 3.50 (m, 1H); 3.69 (d, $J = 8.0$ Hz, 1H); 3.92 (m, 1H); from 4.19 to 4.38 (m, 3H); 4.52 (broad s, 1H); 5.36 (dd, $J = 7.5$ and 16.0 Hz, 1H); 5.58 (dd, $J = 8.0$ and 16.0 Hz, 1H); 7.10 (d, $J = 8.5$ Hz, 1H); 7.36 (t, $J = 7.5$ Hz, 1H); 7.46 (t, $J = 7.5$ Hz, 2H); 7.58 (broad d, $J = 8.5$ Hz, 1H); 7.62 (broad s, 1H); 7.69 (d, $J = 7.5$ Hz, 2H); 8.02 (d, $J = 8.0$ Hz, 1H); 9.92 (s, 1H).

Ex6: (2*R*,3*R*,4*S*,5*R*,6*E*)-7-cyclopentyl-3,4,5-trihydroxy-2-methoxy-*N*-[(3*S*-1-methyl-2-oxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-3-yl)]hept-6-enamide



20

Step 1: Preparation of *tert*-butyl [(3*S*)-1-methyl-2-oxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-3-yl]carbamate (**7a**)




0.898 mg of sodium hydride in suspension at 60% in oil (22.44 mmol) is introduced, at AT, into a 500 ml round-bottomed flask, with stirring and under an argon atmosphere, containing 260 ml of THF and 6.2 g of **2a** (22.44 mmol). The medium is stirred for 1 h and then 3.823 g (26.94 mmol) of methyl iodide are added. The medium is left stirring overnight, 500 ml of EtOAc are added and the organic phase is washed twice with 500 ml of water. The organic phase is dried over MgSO₄, filtered and then evaporated to dryness. 6.85 g of crude product are obtained. After chromatography on a silica cartridge (250 g, eluent heptane/EtOAc - as an EtOAc gradient: 10 to 50%). 4.47 g of product **7a** (white solid) are obtained.

Mp = 133.2 +/- 1°C

[α]_D: -204.8 +/- 2.2 (c = 2.484 mg/0.5 ml MeOH)

Step 2: Preparation of (3S)-3-amino-1-methyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one hydrochloride (**8a**)




4.36 g of **7a** (15.01 mmol) are taken up in a 250 ml round-bottomed flask and 110 ml of a solution of hydrochloric acid in dioxane (4M) are added. The mixture is stirred for 4 h at AT under argon. After the solvent has been evaporated off, the solid is disintegrated with 25 ml of isopropyl ether, and filter-dried over sintered glass. After drying, 3.1 g of amine **8a** in hydrochloride form are obtained, which amine is used directly for the following step.

Mp = 221.7 +/- 1°C

[α]_D: -257.1 +/- 2.8 (c = 2.696 mg/0.5 ml MeOH).

Step 3: Preparation of (2R,3R,4S,5R,6E)-7-cyclopentyl-3,4,5-trihydroxy-2-methoxy-N-[(3S)-1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]hept-6-enamide (**Ex6**)



100 mg of **19** (0.39 mmol), 88.42 mg of **8a** (0.39 mmol) and 162 mg of sodium 2-ethylhexanoate (0.98 mmol) in 2.0 ml of THF are successively introduced into a Wheaton tube, with agitation and under an argon atmosphere. The agitation is maintained at AT for 24 h. The reaction medium is directly evaporated to dryness. The crude is chromatographed on a silica cartridge (12 g, eluent EtOAc), and 60 mg of expected product **Ex6** (white solid) are obtained.

ES: $m/z = 447 \text{ MH}^+$.

- 10 ^1H NMR (500 MHz, DMSO-d_6), $\delta(\text{ppm})$: 1.21 (m, 2H); from 1.41 to 1.73 (m, 6H); 2.03 (m, 1H); 2.20 (m, 1H); 2.37 (m, 1H); from 2.60 to 2.75 (m, 2H); 3.21 (s, 3H); from 3.25 to 3.35 (m masked, 1H); 3.30 (s, 3H); 3.48 (m, 1H); 3.66 (d, $J = 8.0 \text{ Hz}$, 1H); 3.91 (m, 1H); 4.20 (m, 1H); 4.29 (m, 2H); 4.53 (d, $J = 4.0 \text{ Hz}$, 1H); 5.35 (dd, $J = 7.5$ and 16.0 Hz , 1H); 5.57 (dd, $J = 8.5$ and 16.0 Hz , 1H); 7.23 (m, 1H); 7.31 (d, $J = 7.5 \text{ Hz}$, 1H); 7.39 (m, 2H); 8.04 (d, $J = 8.0 \text{ Hz}$, 1H).

Biological activity of the products prepared:

- On the day the application was filed, it was measured that the $\text{CaCO}_2\text{-TC7}$ of the product of Example 4a (Papp single point = $48.10^{-7} \text{ cm}\cdot\text{sec}^{-1}$) is better than that of the product of Example 22a (Papp single point = $6.10^{-7} \text{ cm}\cdot\text{sec}^{-1}$) described in patent application WO 2006/056696.







- The antiproliferative activity of the products of the examples of Table 1 was determined by measuring the inhibition of the cell proliferation of HCT116 cells. The cells are seeded into a cell culture medium at a concentration of 10 000 cells per well, in 0.17 ml of medium, and 20 μl of test product, at various concentrations and 10 μl of thymidine [methyl- ^{14}C] (100 $\mu\text{Ci/ml}$ – specific activity 47.90 mCi/mmol; NEN Technologies reference NEC568 batch 3550-001) are added and the cells are then incubated at 37°C and 5% CO_2 .



Medium used for the HCT116 cell culture: DMEM medium, 2 mM L-glutamine,

200 IU/ml penicillin, 200 μ g/ml streptomycin and 10% (V/V) foetal calf serum (Life Technologies).

- After 96 hours, the 14 C-thymidine incorporation is counted in a 1450 Microbeta Wallac Trilux liquid scintillation counter. The results R are expressed in cpm (counts per minute) and converted to percentage growth inhibition GI% by firstly subtracting the mean of the number of cpm of the wells without cells B and then dividing by the number of cpm of the wells of the nontreated cells C comprising 20 μ l of product diluting medium containing 1% of ethanol ($GI\% = (R - B) \times 100/C\%$).
- 10 The IC₅₀ values are calculated using equation 205 of the XLFit software (IDBS company, UK) by nonlinear regression analysis using the Marquardt algorithm (Donald W. MARQUARDT, J.Soc.industry.appl, vol 11, No. 2, June, 1963).
- 15 The products in Table 1 have an IC₅₀ on HCT116 cells that is generally less than 30 μ M, and preferably less than 100 nM. For example, the product of Example 1 has an IC₅₀ of 14 nM and the product of Example 3 has an IC₅₀ of 58 nM. The product of Example 2 has an IC₅₀ of 15 nM, the product of Example 3a has an IC₅₀ of 32 nM, the product of Example 4 has an IC₅₀ of 75 nM and the product of Example 4a has an IC₅₀ of 14 nM.
- 20


- Table 1 -

Example	Structure
Ex1	
Ex2	
Ex3	
Ex3a	
Ex4	
Ex4a	

Ex5	
Ex6	

CLAIMS

1. Product of formula (I) below:




in which:

- 5 a) R_1 is independently selected from the group consisting of (C_1-C_{12}) alkyl, (C_2-C_{12}) alkenyl, (C_2-C_{12}) alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkyl (C_1-C_{12}) alkyl, cycloalkyl (C_2-C_{12}) alkenyl, cycloalkyl (C_2-C_{12}) alkynyl, heterocyclyl (C_1-C_{12}) alkyl, heterocyclyl (C_2-C_{12}) alkenyl, heterocyclyl (C_2-C_{12}) alkynyl, aryl (C_1-C_{12}) alkyl, aryl (C_2-C_{12}) alkenyl, aryl (C_2-C_{12}) alkynyl, heteroaryl (C_1-C_{12}) alkyl, heteroaryl (C_2-C_{12}) alkenyl, heteroaryl- (C_2-C_{12}) alkynyl, the aryl group of each R_1 being optionally substituted with one or more halogens;
- 10 b) R_2 is selected from the group consisting of (C_1-C_6) alkyl, aryl (C_1-C_6) alkyl, heteroaryl (C_1-C_6) alkyl, aryl, heteroaryl, (C_1-C_6) alkylthio (C_1-C_6) alkyl, di (C_1-C_6) alkylamino (C_1-C_6) alkyl, aryloxy (C_1-C_6) alkyl, (C_1-C_6) alkoxy (C_1-C_6) alkyl;
- 15 c) R_3 is selected from the group consisting of H, $COO(R_5)$, $CONH(R_5)$, $CO(R_5)$, $O(R_5)$ and R_5 ;
- 20 d) R_4 is independently selected from the group consisting of H, F, Cl, Br, $N(R_5)_2$, NO_2 , CN, $COO(R_5)$, $CON(R_5)_2$, $NHCO(R_5)$, $NHCOO(R_5)$, $OCONH(R_5)$, $O(R_5)$ and R_5 , or else two substituents R_4 , attached to 2 adjacent carbons of the phenyl, together form a ring selected from a cycloalkyl, heterocyclyl, aryl or heteroaryl, optionally substituted with one or more R_4 ;
- 25

e) m has the value 0, 1, 2, 3 or 4;

f) R_5 is independently selected from a doublet of nonbonding electrons, H, (C_1-C_{12}) alkyl, (C_2-C_{12}) alkenyl, (C_2-C_{12}) alkynyl, halo (C_1-C_{12}) alkyl, aryl (C_1-C_{12}) alkyl, heteroaryl (C_1-C_{12}) alkyl, heteroarylaryl (C_1-C_{12}) alkyl, aryl, heteroaryl and cycloalkyl, in which each R_5 is optionally substituted with at least one substituent selected from OH, halogen, (C_1-C_4) alkyl, (C_1-C_4) alkoxy, aryl (C_1-C_4) alkyl, aryl, heteroaryl (C_1-C_4) alkyl, heteroaryl, $-N(CH_3)_2$, $-NH_2$, $CONH_2$.



each of the R_z is independently selected from the group consisting of H, $COO(R_5)$, $CONH(R_5)$, $CON(R_5)_2$, $CO(R_5)$ and R_5 , in which each R_5 is independently selected from (C_1-C_4) alkyl, halo (C_1-C_4) alkyl, aryl (C_1-C_4) alkyl and heteroaryl (C_1-C_4) alkyl, in which each R_5 is optionally substituted with a substituent selected from OH, halogen, (C_1-C_4) alkyl, (C_1-C_4) alkoxy, aryl (C_1-C_4) alkyl, aryl, heteroaryl (C_1-C_4) alkyl and heteroaryl;

with the proviso that, when R_1 is (E) $-CH=CH-C(CH_3)_3$, R_2 is methyl and R_3 is H, then m is other than 0.

2. Product according to Claim 1, characterized in that R_1 is selected from $-C(R_6)=C(R_7)(R_8)$ in which R_6 , R_7 and R_8 are independently selected from H, (C_1-C_6) alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl.
3. Product according to Claim 2, characterized in that R_1 is selected from (E) $-CH=CH-CH(CH_3)(C_2H_5)$, (E) $-CH=CH-CH(CH_3)_2$ and (E) $-CH=CH-C(CH_3)_3$.
4. Product according to Claim 2, characterized in that R_1 is selected from (E) $-C(CH_3)=CH-CH(CH_3)(C_2H_5)$, (E) $-C(CH_3)=CH-CH(CH_3)_2$ and (E)



5. Product according to any one of Claims 1 to 4, characterized in that R_2 is methyl.
6. Product according to any one of Claims 1 to 5, characterized in that R_3 is independently selected from: a methyl group or a (3,5-difluorophenyl)methyl group.
7. Product according to any one of Claims 1 to 5, characterized in that R_3 is H.
8. Product according to any one Claims 1 to 7, characterized in that R_4 is independently selected from: F, Cl, Br, phenyl and pyridinyl.
9. Product according to any one of Claims 1 to 7, characterized in that m is 0.
10. Product according to any one of Claims 1 to 9, characterized in that it is selected from:
15 N-[1-(3,5-difluorobenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-((E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide;
N-[1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-((E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide;
20 N-((3S)-7-bromo-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide;
N-((3S)-7-phenyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide.
25
11. Product according to any one of Claims 1 to 9, characterized in that it is selected from:

(2R,3R,4S,5R,6E)-7-cyclopentyl-3,4,5-trihydroxy-2-methoxy-N-[(3S)-1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]hept-6-enamide;

5 (2R,3R,4S,5R,6E)-7-cyclopentyl-3,4,5-trihydroxy-2-methoxy-N-[(3S)-2-oxo-7-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]hept-6-enamide.

12. Product according to any one of the preceding claims, characterized in that it is:

- 10 a) in nonchiral form, or
b) in racemic form, or
c) in a form enriched in a stereoisomer, or
d) in a form enriched in an enantiomer;

and in that it is optionally salified.

15 13. Medicament, characterized in that it comprises a product of formula (I) according to any one of Claims 1 to 12, or an addition salt of this product with a pharmaceutically acceptable acid, or alternatively a hydrate or a solvate of the product of formula (I).


20 14. Pharmaceutical composition, characterized in that it comprises a product of formula (I) according to any one of Claims 1 to 12, or a pharmaceutically acceptable salt, a hydrate or a solvate of this product, and also at least one pharmaceutically acceptable excipient.

25 15. Use of a product according to any one of Claims 1 to 12, for the manufacture of a medicament that can be used for preventing or treating a pathological condition.

16. Use according to Claim 15, characterized in that the pathological condition is cancer.


17. Process for preparing the products of formula (I) according to any one

of Claims 1 to 12, or (I'), characterized in that a product of formula (II):




, in which R₁, R₂, R₃, R₄ and m are as defined above, is subjected to a hydrolysis so as to obtain a product of formula (I) or (I').

- 5 18. Process for preparing, according to Claim 17, a product of formula (I) according to one of Claims 1 to 12, or (I'), characterized in that a product of formula (III):




, in which R₃, R₄ and m are as defined above, is reacted with a product of formula (IV):




- 10 , in which R₁ and R₂ are as defined above, so as to obtain a product of formula (II).

19. Process for preparing a product of formula (I) according to any one of Claims 1 to 12, or (I'), characterized in that a product of formula (III):




, in which R₃, R₄ and m are as defined above, and a product of formula (V):



(V)


, in which R_1 and R_2 are as defined above, are reacted so as to obtain a product of formula (I) or (I').

20. Process for preparing, according to Claim 19, a product of formula (I) according to one of Claims 1 to 11, or (I'), characterized in that a product of formula (IV):



(IV)


, in which R_1 and R_2 are as defined above, is subjected to a hydrolysis so as to obtain a product of formula (V):



(V)


, in which R_1 and R_2 are as defined above.

21. Process for preparing, according to Claim 19, a product of formula (I) according to one of Claims 1 to 12, or (I'), characterized in that a product of formula (VII):




(VII)

, in which R_2 is as defined above, is subjected to a hydrolysis in order to obtain a product of formula (VI):



(VI)


, in which R_2 is as defined above, which is subjected to a metathesis in order to obtain a product of formula (V):



(V)


, for which R_1 is $-\text{CH}=\text{CH}-R'_1$ and R'_1 is a $(\text{C}_1\text{-C}_6)$ alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group.

22. Process for preparing, according to Claim 21, a product of formula (I) according to one of claims 1 to 12, or (I'), characterized in that a product of formula (VII):



(VII)

, in which R_2 is as defined above, is obtained by double dehydration of a product of formula (VIII):



(VIII)

, in which R_2 is as defined above.

23. Products of formula (I') and (II) as defined in Claims 17 to 22, with the exception of those for which R_1 is (E) $-\text{CH}=\text{CH}-\text{C}(\text{CH}_3)_3$, R_2 is methyl, R_3 is H and m is 0.
24. Products of formula (III), characterized in that R_3 is H, methyl or (3,5-difluorophenyl)methyl and R_4 is a bromine atom or a phenyl or else m has the value 0, with the exception of those for which R_3 is H and m has the value 0.
25. Products of formulae (IV) and (V), characterized in that R_2 is methyl and R_1 is $-(\text{E})-\text{CH}=\text{CH}-\text{C}_5\text{H}_9$.
26. Products of formula (VI), characterized in that R_2 is methyl.